Drug Discovery World

JULY 6, 2023

The first patient has been dosed in the clinical Phase I evaluation of the Sema3A monoclonal antibody, part of the Evotec-Bayer multi-target research collaboration in kidney diseases. Semaphorin-3A is an extracellular guidance protein and a well-known regulator of the actin cytoskeleton.

Antibody 52

Antibody Trials Genetics Protein 52

Bio Pharma Dive

JUNE 5, 2023

Results from a “basket” trial of the antibody-drug conjugate show it shrank tumors across a half dozen cancers, suggesting a broader role to targeting the protein HER2.

Drugs 177

Drugs Protein Antibody Trials 177

Drug Discovery World

MARCH 12, 2024

Here, experts weigh in on the future of monoclonal antibodies (mAbs). Amanda Halford, President Bioprocess, Cytiva “In 2024, the emphasis will remain on novel mAbs, specifically antibody drug conjugates. Secondary, there is a growing interest in replacing the cytotoxic head with non-toxic alternatives, like protein degraders.

Antibody 81

Antibody FDA Approval Drugs Development 81

pharmaphorum

SEPTEMBER 16, 2020

Regeneron’s COVID-19 antibody cocktail has been added to the UK’s RECOVERY trial, one of the largest of its kind in the world that is testing several potential coronavirus therapies at the same time. REGN-COV2 is a combination of two monoclonal antibodies, designed to block infections of SARS-CoV-2, the virus that causes COVID-19.

Antibody 96

Antibody Trials Manufacturing Protein 96

Pharmaceutical Technology

JUNE 20, 2023

Developed using pharmaceutical company GSK’s pandemic adjuvant, the vaccine targets the receptor-binding domain of the SARS-CoV-2 spike protein. The vaccine is based on recombinant protein vaccine technology and is suitable for storage between 2°C and 8°C.

Vaccination 363

Vaccination Vaccine Protein Clinical Trials 363

XTalks

MAY 7, 2021

As Novavax awaits emergency use authorization (EUA) from the US Food and Drug Administration (FDA) for its protein-based COVID-19 vaccine NVX-CoV2373, the company shared new data this week on the vaccine’s efficacy against the South African B.1.351 These results came from data from Novavax’s Phase III UK trial where B.1.117

Protein 97

Protein Vaccination Vaccine Trials 97

pharmaphorum

JULY 27, 2022

Pfizer and BioNTech have started a mid-stage trial of a new version of the COVID-19 vaccine based on a version of the spike protein that they hope will offer greater and broader protection against SARS-CoV-2 variants. Clinical data show strong neutralising antibody responses against Omicron BA.1, 1 subvariant of Omicron.

Protein 122

Protein Immune Response Vaccination Vaccine 122

Drug Discovery World

MAY 21, 2024

Ben Holland , CTO and Co-Founder of Antiverse discusses how artificial intelligence and machine learning are benefitting antibody discovery and design. Modern experimental procedures, such as immunisation, B-cell screening, and synthetic library generation, have been pivotal in developing approximately 80 FDA-approved antibody therapeutics.

Antibody 59

Antibody Development FDA Approval Contract Manufacturing 59

XTalks

MAY 9, 2024

Genmab, a trailblazer in the field of antibody therapeutics, celebrates this milestone by reflecting on its impressive journey from a small-scale startup to a global leader in cancer treatment and beyond. Since then, innovative science has been at Genmab’s core, as we harness the power of human antibodies to improve the lives of patients.

Antibody 52

Antibody Clinical Trials Clinical Trials Medicine 52

Drug Discovery World

JUNE 1, 2023

Antibody-drug conjugates (ADCs) are biopharmaceutical products in which a monoclonal antibody (mAB) is linked to a small molecule drug with a stable linker 1. To overcome this challenge, Synaffix has developed an innovative technology platform that can rapidly and efficiently convert any antibody into an ADC.

Antibody 98

Antibody Marketing Drugs Licensing 98

Pharmaceutical Technology

JUNE 9, 2023

5+delta) protein vaccine (Sf9 cell). The subunit antigen in the vaccine has been based on the structure of the targeting S-RBD and HR proteins of the XBB and BA.5 It is self-assembled into stable trimeric protein particles with the addition of squalene-based oil-in-water emulsion adjuvant following purification and mixing.

Vaccination 269

Vaccination Vaccine HR Protein 269

pharmaphorum

JUNE 17, 2021

Biogen has four other Alzheimer’s candidates in its clinical pipeline behind recently-approved Aduhelm, but one of them – anti-tau antibody gosuranemab – has just been canned. In Alzheimer’s, the protein runs amok, forming tangles that have been linked to cell damage and neuronal death.

Antibody 98

Antibody Protein Licensing Licensing 98

pharmaphorum

SEPTEMBER 30, 2020

Regeneron’s antibody cocktail seems to reduce levels of coronavirus and improve symptoms in patients, according to early test results. This first data comes from a descriptive analysis from the seamless phase 1/2/3 trial that Regeneron hopes will hurry the medicine dubbed REGN-COV2 to market. There were no deaths in the trial.

Antibody 135

Antibody Immune Response Trials Protein 135

pharmaphorum

OCTOBER 25, 2021

Expectations for Novartis’ canakinumab as a therapy for cancer have taken another dive, after a second phase 3 trial in non-small cell lung cancer (NSCLC) failed to meet its primary objectives. The post Strike two for Novartis’ lung cancer antibody canakinumab appeared first on.

Antibody 116

Antibody Trials Branding Sales 116

pharmaphorum

SEPTEMBER 17, 2020

Eli Lilly has followed up supportive data from its Olumiant in COVID-19 with results of a study showing its antibody treatment could help prevent hospitalisation from the disease. The double-blind placebo-controlled antibody study involved patients with symptoms outside hospitals, who were treated with four different dose strengths.

Antibody 115

Antibody RNA Trials Clinical Trials 115

Drug Discovery World

NOVEMBER 14, 2023

DDW’s Megan Thomas looks at how different diseases will benefit from the success of therapeutic antibodies. Cancer Monoclonal antibodies (mAbs) are a type of targeted drug therapy, and as such are often used to treat cancer. The global arthritis monoclonal antibodies market grew from $49.44 billion in 2022 to $53.81

Antibody 59

Antibody Development FDA Approval Trials 59

pharmaphorum

APRIL 19, 2021

The EMA has started reviewing the emergency use application for GlaxoSmithKline and Vir Biotech’s COVID-19 antibody VIR-7831, which could become the fourth drug of its type cleared for early use in the EU. .

Antibody 98

Antibody Protein Development Drugs 98

Roots Analysis

AUGUST 9, 2023

Novel antibody therapies are chimeric proteins having antibodies attached lethal effector molecules. Multiple novel antibody formats have been engineered to enhance therapeutic efficacy. Around 50% of the articles focused on novel antibody therapies were published post-2020.

Antibody 52

Antibody Marketing Development Engineer 52

pharmaphorum

MARCH 30, 2021

Two antibodies targeting different parts of the COVID-19 virus spike protein, from Eli Lilly and GlaxoSmithKline/Vir Biotech, can cut viral load dramatically within a week. . The post Lilly and GSK/Vir antibody pairing offers resistant COVID-19 hope appeared first on.

Antibody 93

Antibody Protein Trials Regulation 93

Scienmag

APRIL 13, 2022

A new protein-based antiviral nasal spray developed by researchers at Northwestern University, University of Washington and Washington University at St. Louis is being advanced toward Phase I human clinical trials to treat COVID-19.

Antibody 88

Antibody Protein Clinical Trials Clinical Trials 88

pharmaphorum

OCTOBER 8, 2020

Eli Lilly has asked the FDA for an Emergency Use Authorization for its COVID-19 antibody therapy, after announcing new efficacy data from an ongoing trial. The big US pharma is asking for an emergency approval of the monotherapy version of its antibody therapy codenamed LY-CoV555.

Antibody 98

Antibody Clinical Trials Clinical Trials Trials 98

Pharmaceutical Technology

NOVEMBER 14, 2022

The antibody-drug conjugate (ADC) treatment is indicated for such patients who have previously received one to three systemic therapy regimens, irrespective of the usage of Avastin priorly. Elahere obtained the approval based on the findings on objective response rate (ORR) and duration of response (DOR) reported in the SORAYA clinical trial.

FDA Approval 246

FDA Approval Antibody Clinical Trials Clinical Trials 246

BioSpace

APRIL 1, 2021

One of the common research approaches to treating brain diseases such as Parkinson’s disease (PD) and Alzheimer’s disease (AD) is using antibodies designed to clear the accumulated misfolded proteins implicated in the diseases. To date, these drug trials have not been particularly successful at i.

Protein 68

Protein Drug Trials Antibody Trials 68

Drug Discovery World

MARCH 8, 2024

The top stories: Antibody therapy shows anti-tumour activity in advanced cancer In an early phase clinical trial, a combination of antibody-based medications targeting the immune system generated promising safety data and anti-tumour activity in individuals with advanced cancer.

Antibody 52

Antibody Drugs Clinical Trials Clinical Trials 52

Pharmaceutical Technology

JANUARY 19, 2023

This DUX4 protein abnormal expression leads to modifications in gene expression in muscle cells which are associated with progressive muscle function loss in FSHD patients. Avidity Biosciences’ AOC 1020 is intended to reduce the DUX4 mRNA and DUX4 protein expression in muscles in these patients.

Gene Expression 246

Gene Expression Gene Protein RNA 246

Pharmaceutical Technology

FEBRUARY 3, 2023

Only a few weeks into the new year, the prospect of getting a successful advanced HIV vaccine shrank after the discontinuation of yet another late-stage trial. This marks the second time one of Janssen’s HIV vaccines failed after another showed disappointing results in the Phase IIb Imbokodo trial in August 2021.

Vaccination 293

Vaccination Vaccine Antibody Trials 293

Pharmaceutical Commerce

FEBRUARY 6, 2024

BioNTech SE and Duality Biologics Co's BNT325/DB-1305 is a next-generation antibody-drug conjugate that targets the TROP2 protein, which is overexpressed across various tumor types.

Protein 52

Protein Antibody Trials Drugs 52

Pharmaceutical Technology

DECEMBER 7, 2022

Health Canada has granted approval for a supplement to a New Drug Submission (sNDS) of Novavax ’s Covid-19 vaccine (Recombinant protein, Adjuvanted), Nuvaxovid (NVX-CoV2373), for use in adolescents aged 12 to 17 years. The trial is designed to analyse the safety and effectiveness of the vaccine.

Vaccination 264

Vaccination Vaccine Protein Clinical Trials 264

Drug Discovery World

SEPTEMBER 25, 2023

Enrolment in a Phase I trial of a new investigational universal influenza vaccine candidate has begun at the National Institutes of Health’s Clinical Center in Bethesda, Maryland, US. With each new universal influenza vaccine candidate and clinical trial, we take another step closer to that goal,” said Acting NIAID Director Hugh Auchincloss.

Vaccination 52

Vaccination Vaccine Trials Immune Response 52

XTalks

JULY 25, 2022

The BLA, which grants permission to distribute a biological therapy across states in the US, was accepted based on data from the company’s Phase III trial. Epidermal growth factor receptor 2 (HER2)-positive breast cancer is one such type in which there is an overexpression of the HER2 protein.

Antibody 59

Antibody Drugs Clinical Trials Clinical Trials 59

XTalks

JUNE 18, 2021

This is why Regeneron’s announcement of positive clinical trial results that show its antibody cocktail treatment can cut deaths among hospitalized patients is welcome news. It is the first trial to demonstrate that any antibody treatment could improve survival in patients hospitalized with COVID-19.

Antibody 75

Antibody Immune Response Trials Clinical Trials 75

Pharmaceutical Technology

JUNE 14, 2023

Inobrodib is an oral first-in-class cancer drug, indicated for patients who have previously received four or more lines of therapy, including an anti-CD38 monoclonal antibody, an immunomodulatory agent and a proteasome inhibitor. It inhibits p300 and CBP by binding into the conserved bromodomain of the twin proteins.

Protein 243

Protein Antibody Gene Trials 243

The Pharma Data

APRIL 15, 2022

A new protein-based antiviral nasal spray developed by researchers at Northwestern University, University of Washington and Washington University at St. Louis is being advanced toward Phase I human clinical trials to treat COVID-19. “Our minibinders sit on top of the spike protein like a tripod and block all three.

Antibody 52

Antibody Protein Engineer Manufacturing 52

pharmaphorum

MAY 19, 2022

Moderna has joined forces with non-profit organisation IAVI on a third phase 1 trial of its candidate HIV vaccine in Africa, where the burden of the virus is still being keenly felt. One candidate – mRNA-1644 – has already shown its potential in an earlier phase 1 trial (IAVI G001) run in the US.

Vaccination 145

Vaccination Vaccine Trials Immune Response 145

Drug Discovery World

MARCH 22, 2023

Preventing metastatic progression NETs are web-like DNA structures and are covered with cancer-promoting proteins that are released by activated neutrophils and that have been shown to engulf tumours and promote immune evasion, tumour progression and metastases.

Antibody 52

Antibody Protein DNA Drugs 52

Pharmaceutical Technology

MARCH 17, 2023

This collaboration is intended to fund up to three research grants that are focused on antibody-drug conjugates (ADCs) for improving the outcomes for lung cancer patients. An ADC includes a monoclonal antibody, which helps recognise a protein that is present in the cancer cells and is bound to the payload, a cytotoxic agent.

Research 246

Research Antibody Protein Trials 246

pharmaphorum

MAY 10, 2021

The EMA has begun a rolling review of a COVID-19 antibody developed by GlaxoSmithKline and Vir BioTech which could become the fourth drug of its type cleared for early use in the EU. . Other data such as final clinical trial results will be assessed in due course. EMA_News starts evaluating the monoclonal antibody sotrovimab.

Antibody 52

Antibody Protein Trials Clinical Trials 52